Seres Therapeutics, Inc.
MCRB
$7.84
-$0.12-1.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -21.28% | -38.68% | -7.45% | -- | 1,847.99% |
| Gross Profit | 22.02% | 50.56% | 7.45% | -- | -1,847.99% |
| SG&A Expenses | -39.50% | -25.44% | -21.52% | -20.45% | -10.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.28% | -21.74% | -13.82% | -20.91% | -22.12% |
| Operating Income | 32.80% | 22.94% | 13.82% | 20.91% | 22.12% |
| Income Before Tax | 1.93% | 116.08% | 24.21% | 199.33% | 54.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.93% | 116.08% | 24.21% | 199.33% | 54.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.93% | -90.76% | 39.60% | 181.43% | 62.09% |
| EBIT | 32.80% | 22.94% | 13.82% | 20.91% | 22.12% |
| EBITDA | 33.61% | 22.81% | 13.22% | 20.44% | 21.59% |
| EPS Basic | 8.99% | -91.95% | 47.66% | 168.35% | 71.21% |
| Normalized Basic EPS | -841.07% | 67.53% | 33.72% | 50.26% | 104.55% |
| EPS Diluted | 9.37% | -91.94% | 47.69% | 168.26% | 71.16% |
| Normalized Diluted EPS | -841.07% | 67.58% | 33.72% | 50.33% | 104.55% |
| Average Basic Shares Outstanding | 7.75% | 14.76% | 15.42% | 19.14% | 31.65% |
| Average Diluted Shares Outstanding | 7.75% | 14.93% | 15.42% | 19.30% | 31.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |